This systematic review and meta-analysis of 18 cohort studies, encompassing over 1,000,000 individuals with type 2 diabetes, evaluated the potential effectiveness and safety of combining SGLT2 inhibitors and GLP-1 RAs compared with monotherapy with either an SGLT2 inhibitor or a GLP-1 RA. Here, SLC5A2 is linked to type 2 diabetes mellitus.